These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31951523)

  • 21. Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
    Hussain R; O'Leary S; Pacheco FM; Zacharias TE; Litvak P; Sguigna P; Marder E; Kia K; Kooner K; Stüve O
    J Neurol; 2016 Mar; 263(3):606-10. PubMed ID: 26914924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trials and therapies in secondary progressive MS, simplified.
    Manouchehri N; Stüve O
    Nat Rev Neurol; 2019 Aug; 15(8):431-432. PubMed ID: 31285578
    [No Abstract]   [Full Text] [Related]  

  • 23. The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
    Samjoo IA; Worthington E; Haltner A; Cameron C; Nicholas R; Dahlke F; Adlard N
    Curr Med Res Opin; 2020 Jul; 36(7):1145-1156. PubMed ID: 32216597
    [No Abstract]   [Full Text] [Related]  

  • 24. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
    Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
    CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis].
    Calfunao S; Carrasco M; Gutierrez C; Cerpa L; Varela N; Quiñones L
    Rev Med Chil; 2023 Oct; 151(10):1375-1384. PubMed ID: 39093141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan].
    Kondo T
    Brain Nerve; 2020 May; 72(5):517-523. PubMed ID: 32381749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS; Kolontareva YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
    Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
    J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
    Sullivan R; Kilaru A; Hemmer B; Campbell Cree BA; Greenberg BM; Kundu U; Hach T; DeLasHeras V; Ward BJ; Berger J
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 9(1):. PubMed ID: 34848501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two New Drugs Approved for Multiple Sclerosis.
    Aschenbrenner DS
    Am J Nurs; 2019 Jul; 119(7):22-23. PubMed ID: 31232771
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Zhao Z; Lv Y; Gu ZC; Ma CL; Zhong MK
    Front Immunol; 2021; 12():795574. PubMed ID: 34950154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
    Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series.
    Zanghì A; Di Filippo PS; Avolio C; D'Amico E
    Mult Scler Relat Disord; 2024 Oct; 90():105795. PubMed ID: 39151236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does Siponimod Exert Direct Effects in the Central Nervous System?
    Kipp M
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
    Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.
    Shakeri-Nejad K; Gardin A; Gray C; Neelakantham S; Dumitras S; Legangneux E
    Clin Ther; 2020 Jan; 42(1):175-195. PubMed ID: 31926605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The first russian experience of use of siponimod in real clinical practice].
    Prakhova LN; Ilves AG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):138-141. PubMed ID: 35904305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action.
    Behrangi N; Fischbach F; Kipp M
    Cells; 2019 Jan; 8(1):. PubMed ID: 30621015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The window of opportunity for treatment of progressive multiple sclerosis.
    Sorensen PS; Fox RJ; Comi G
    Curr Opin Neurol; 2020 Jun; 33(3):262-270. PubMed ID: 32251026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
    Uosef A; Vaughn N; Chu X; Elshawwaf M; Abdelshafy AAA; Elsaid KMK; Ghobrial RM; Kloc M
    Arch Immunol Ther Exp (Warsz); 2020 Jun; 68(3):19. PubMed ID: 32488676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.